Oncology

Pharmacists should be aware of the impacts that anemia in patients being treated for cancer has on daily activities and overall quality of life.

Compliance is achievable for outpatient oncology practices with careful planning and execution.

Patients with hormone receptor–positive and human epidermal growth factor receptor 2 breast cancer are particularly at risk.

Patients with relapsed, refractory disease achieved deep, durable responses with equecabtagene autoleucel.

The model, Deep-IO, shows improved specificity and sensitivity compared with existing predictive biomarkers.

Treatment options may include treating the anemia with blood transfusions, androgen therapy, thalidomide, and other medications.

Tislelizumab is approved in combination with platinum and fluoropyrimidine-based chemotherapy as first-line treatment of unresectable or metastatic HER2-negative tumors.

The approval offers patients with solid tumors an alternative to intravenous PD-1 inhibitor administration.

The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.

Bispecific antibodies amivantamab and tarlatamab hold promise for patients.

Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia.

The program develops patient-centered oncology pharmacists through comprehensive training.

Yi Lin, MD, PhD, highlights the importance of achieving MRD negativity in multiple myeloma, CAR T-cell therapy outcomes, and the critical role of pharmacists in patient care.

Here is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.

Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.

This study evaluated factors affecting the duration of the infusion appointment times for 392 clinical trial patients.

Of these chemicals, 414 were found to be commonly used in plastics and consumer goods, such as food packaging and personal care products.

Pharmacists bring a unique perspective to health care that bridges clinical knowledge, patient-centered care, and operational expertise.

Pharmacy Times attended the 2024 San Antonio Breast Cancer Symposium from December 10 to December 13.

The treatment landscape for multiple myeloma continues to evolve.

A study in Lancet Haematology revealed that minority ethnic patients face significantly poorer outcomes after hematopoietic cell transplantation compared to White patients.

Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.

This case highlights the importance of recognizing ICPI-AKI, implementing effective therapeutic interventions, and understanding the clinical context to prevent irreversible renal damage.

The indication is for patients with locally advanced or metastatic disease who have not previously received treatment with an ALK-inhibitor.

The researchers suggest that an imbalance between pro-inflammatory and resolving lipid mediators may drive tumor growth.

The radiation emerging from these isotopes can be used in 2 different ways in cancer trials: imaging (detection of tumors) and therapy (destruction of tumors).

Firas El Chaer, MD, discusses newly-presented data at ASH demonstrating nuvisertib's effectiveness in myelofibrosis.

Abstract data presented in September demonstrate that the drug elicited strong antitumor activity in the second line in both platinum-sensitive and -resistant patients.